Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
ACAD Analyst Ratings
Moderate Buy
9 Buy
6 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ACAD Stock 12 Month Forecast
Average Price Target
$26.14
▲(52.07% Upside)
| Highest Price Target$37.00 | Average Price Target$26.14 | Lowest Price Target$18.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Morgan Stanley
Initiated
03/07/25
J.P. Morgan
Reiterated
03/03/25
Cantor Fitzgerald
Reiterated
02/27/25
Leerink Partners
Reiterated
02/27/25
Guggenheim
Reiterated
02/27/25
H.C. Wainwright
Reiterated
02/27/25
Mizuho Securities
Reiterated
02/27/25
Needham
Reiterated
02/27/25
Canaccord Genuity
Reiterated
02/27/25
Stifel Nicolaus
Reiterated
02/27/25
Bank of America Securities
―
Hold
―
Reiterated
02/27/25
ACADIA Pharmaceuticals (ACAD) Receives a Hold from Bank of America Securities
JMP Securities
$39→$37
Buy
115.24%
Upside
Reiterated
02/27/25
Promising Growth Trajectory and Strategic Investments Drive Buy Rating for ACADIA PharmaceuticalsWe have maintained our peak sales projection for DAYBUE of >$700MM.
TD Cowen
$35
Buy
103.61%
Upside
Reiterated
02/26/25
ACADIA Pharmaceuticals: Strong Financial Performance and Growth Prospects Justify Buy Rating
RBC Capital
$26
Buy
51.25%
Upside
Reiterated
02/26/25
Analysts' Top Healthcare Picks: ACADIA Pharmaceuticals (ACAD), Health Catalyst (HCAT)
Deutsche Bank
$22
Hold
27.98%
Upside
Initiated
02/11/25
Acadia Pharmaceuticals initiated with a Hold at Deutsche BankAcadia Pharmaceuticals initiated with a Hold at Deutsche Bank
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Morgan Stanley
Initiated
03/07/25
J.P. Morgan
Reiterated
03/03/25
Cantor Fitzgerald
Reiterated
02/27/25
Leerink Partners
Reiterated
02/27/25
Guggenheim
Reiterated
02/27/25
H.C. Wainwright
Reiterated
02/27/25
Mizuho Securities
Reiterated
02/27/25
Needham
Reiterated
02/27/25
Canaccord Genuity
Reiterated
02/27/25
Stifel Nicolaus
Reiterated
02/27/25
Bank of America Securities
―
Hold
―
Reiterated
02/27/25
ACADIA Pharmaceuticals (ACAD) Receives a Hold from Bank of America Securities
JMP Securities
$39→$37
Buy
115.24%
Upside
Reiterated
02/27/25
Promising Growth Trajectory and Strategic Investments Drive Buy Rating for ACADIA PharmaceuticalsWe have maintained our peak sales projection for DAYBUE of >$700MM.
TD Cowen
$35
Buy
103.61%
Upside
Reiterated
02/26/25
ACADIA Pharmaceuticals: Strong Financial Performance and Growth Prospects Justify Buy Rating
RBC Capital
$26
Buy
51.25%
Upside
Reiterated
02/26/25
Analysts' Top Healthcare Picks: ACADIA Pharmaceuticals (ACAD), Health Catalyst (HCAT)
Deutsche Bank
$22
Hold
27.98%
Upside
Initiated
02/11/25
Acadia Pharmaceuticals initiated with a Hold at Deutsche BankAcadia Pharmaceuticals initiated with a Hold at Deutsche Bank
ACAD Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Jan 25
Feb 25
Mar 25
Strong Buy
10
13
15
18
7
Buy
6
2
3
8
8
Hold
9
6
10
14
12
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
21
28
40
27
Each month's total comprises the sum of three months' worth of ratings.
ACAD Financial Forecast
ACAD Stock Forecast FAQ
What is ACAD’s average 12-month price target, according to analysts?
Based on analyst ratings, ACADIA Pharmaceuticals’s 12-month average price target is $26.14.
What is ACAD’s upside potential, based on the analysts’ average price target?
ACADIA Pharmaceuticals has 52.07% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ACAD a Buy, Sell or Hold?
ACADIA Pharmaceuticals has a consensus rating of Moderate Buy which is based on 9 buy ratings, 6 hold ratings and 0 sell ratings.
What is ACADIA Pharmaceuticals’s price target?
The average price target for ACADIA Pharmaceuticals is $26.14. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $37.00 ,the lowest forecast is $18.00. The average price target represents 52.07% Increase from the current price of $17.19.
The highest analyst price target is $37.00 ,the lowest forecast is $18.00. The average price target represents 52.07% Increase from the current price of $17.19.
What do analysts say about ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of ACAD?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.